Alternative Splicing of the Multidrug Resistance Protein 1/ATP Binding Cassette Transporter Subfamily Gene in Ovarian Cancer Creates Functional Splice Variants and Is Associated with Increased Expression of the Splicing Factors PTB and SRp20
10.1158/1078-0432.ccr-03-0439
Crossref journal-article
American Association for Cancer Research (AACR)
Clinical Cancer Research (1086)
Abstract

Abstract Purpose: Overexpression of multidrug resistance protein 1 (MRP1) confers resistance to a range of chemotherapeutic agents in cell lines and could be involved in clinical drug resistance of some tumor types also. We examined MRP1 expression in a small series of untreated human ovarian tumors and matched normal tissues. Experimental Design: We analyzed ten pairs of snap-frozen ovarian tumor and matched normal total ovarian tissues from the same patients for expression of MRP1 by reverse transcription-PCR. Amplified PCR products were sequenced to reveal splicing events of MRP1. MRP1 splice variants were expressed as enhanced green fluorescent fusion proteins in HEK293T cells to demonstrate their localization in the cell and their activity in conferring resistance to doxorubicin. The expression of splicing factors PTB and SRp20 was examined by Western blot. Results: MRP1 was expressed in all 10 of the pairs of specimens. Multiple MRP1 cDNA fragments of various sizes were amplified between exons 10 and 19. Of interest, more MRP1 cDNA fragments were detected in ovarian tumors than in matched normal tissues in 9 of 10 pairs. We identified 10 splicing forms between exons 10 and 19 of the MRP1 gene with exon skipping ranging from 1 to 7. Amplification of the entire coding region of MRP1 from 1 ovarian tumor revealed >20 splice variants. We found whole and partial exon skipping and partial intron inclusion in these splice variants. We expressed 3 of these MRP1 splice variants in HEK293T cells and found that they appeared to localize to the plasma membrane and were functional in conferring resistance to doxorubicin. In addition, we identified a few nucleotide variations in this gene. To understand the basis for increased splice variants in the tumors, we examined splicing factor expression in these tissues. Western blot analysis revealed that two splicing factors, PTB and SRp20, were overexpressed in most ovarian tumors compared with their matched normal ovarian tissues. Importantly, overexpression of both of these splicing factors was associated with the increased number of MRP1 splicing forms in the ovarian tissues. Conclusion: The MRP1 gene undergoes alternative splicing at a higher frequency in ovarian tumors than in matched normal tissues. Some of these splice variants confer resistance to doxorubicin. Expression of splicing factors PTB and SRp20 is strongly associated with the alternative splicing of the MRP1 gene.

Bibliography

He, X., Ee, P. L. R., Coon, J. S., & Beck, W. T. (2004). Alternative Splicing of the Multidrug Resistance Protein 1/ATP Binding Cassette Transporter Subfamily Gene in Ovarian Cancer Creates Functional Splice Variants and Is Associated with Increased Expression of the Splicing Factors PTB and SRp20. Clinical Cancer Research, 10(14), 4652–4660.

Authors 4
  1. Xiaolong He (first)
  2. P. L. Rachel Ee (additional)
  3. John S. Coon (additional)
  4. William T. Beck (additional)
References 45 Referenced 89
  1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ Cancer statistics, 2003. CA Cancer J Clin, 53: 5-26,  2003. (10.3322/canjclin.53.1.5)
  2. Harries M, Gore M Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol, 3: 529-36,  2002. (10.1016/S1470-2045(02)00846-X)
  3. Herbst AL The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol, 170: 1099-105, discussion 1105–7 1994. (10.1016/S0002-9378(94)70104-0)
  4. Cole SP, Bhardwaj G, Gerlach JH, et al Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258: 1650-4,  1992. (10.1126/science.1360704)
  5. Zaman GJ, Versantvoort CH, Smit JJ, et al Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res, 53: 1747-50,  1993.
  6. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res, 54: 152-8,  1994.
  7. Zaman GJ, Flens MJ, van Leusden MR, et al The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA, 91: 8822-6,  1994. (10.1073/pnas.91.19.8822)
  8. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res, 54: 357-61,  1994.
  9. Cole SP, Sparks KE, Fraser K, et al Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res, 54: 5902-10,  1994.
  10. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem, 269: 27807-10,  1994. (10.1016/S0021-9258(18)46856-1)
  11. Leier I, Jedlitschky G, Buchholz U, et al ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem J, 314: 433-7,  1996. (10.1042/bj3140433)
  12. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta, 1326: 12-22,  1997. (10.1016/S0005-2736(97)00003-5)
  13. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res, 56: 988-94,  1996.
  14. Loe DW, Stewart RK, Massey TE, Deeley RG, Cole SP ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol, 51: 1034-41,  1997. (10.1124/mol.51.6.1034)
  15. Chauncey TR Drug resistance mechanisms in acute leukemia. Curr Opin Oncol, 13: 21-6,  2001. (10.1097/00001622-200101000-00005)
  16. Ota E, Abe Y, Oshika Y, et al Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer, 72: 550-4,  1995. (10.1038/bjc.1995.372)
  17. Nooter K, Brutel de la Riviere G, Look MP, et al The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer, 76: 486-93,  1997. (10.1038/bjc.1997.414)
  18. Endo K, Maehara Y, Ichiyoshi Y, et al Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer, 77: 1681-7,  1996. (10.1002/(SICI)1097-0142(19960415)77:8+<1681::AID-CNCR15>3.0.CO;2-U)
  19. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med, 334: 231-8,  1996. (10.1056/NEJM199601253340405)
  20. Grant CE, Kurz EU, Cole SP, Deeley RG Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA. Genomics, 45: 368-78,  1997. (10.1006/geno.1997.4950)
  21. Garcia-Blanco MA, Jamison SF, Sharp PA Identification and purification of a 62,000-dalton protein that binds specifically to the polypyrimidine tract of introns. Genes Dev, 3: 1874-86,  1989. (10.1101/gad.3.12a.1874)
  22. Graveley BR Sorting out the complexity of SR protein functions. Rna, 6: 1197-211,  2000. (10.1017/S1355838200000960)
  23. Zhang DW, Cole SP, Deeley RG Identification of an amino acid residue in multidrug resistance protein 1 critical for conferring resistance to anthracyclines. J Biol Chem, 276: 13231-9,  2001. (10.1074/jbc.M010008200)
  24. Stamm S Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet, 11: 2409-16,  2002. (10.1093/hmg/11.20.2409)
  25. Maniatis T, Tasic B Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature, 418: 236-43,  2002. (10.1038/418236a)
  26. Proudfoot NJ, Furger A, Dye MJ Integrating mRNA processing with transcription. Cell, 108: 501-12,  2002. (10.1016/S0092-8674(02)00617-7)
  27. Modrek B, Lee C A genomic view of alternative splicing. Nat Genet, 30: 13-9,  2002. (10.1038/ng0102-13)
  28. Caceres JF, Kornblihtt AR Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet, 18: 186-93,  2002. (10.1016/S0168-9525(01)02626-9)
  29. Stoilov P, Meshorer E, Gencheva M, Glick D, Soreq H, Stamm S Defects in Pre-mRNA Processing as Causes of and Predisposition to Diseases. DNA Cell Biol, 21: 803-18,  2002. (10.1089/104454902320908450)
  30. Matsumura Y, Tarin D Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet, 340: 1053-8,  1992. (10.1016/0140-6736(92)93077-Z)
  31. Cannistra SA, Abu-Jawdeh G, Niloff J, et al CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol, 13: 1912-21,  1995. (10.1200/JCO.1995.13.8.1912)
  32. Stickeler E, Kittrell F, Medina D, Berget SM Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene, 18: 3574-82,  1999. (10.1038/sj.onc.1202671)
  33. Helfman DM, Roscigno RF, Mulligan GJ, Finn LA, Weber KS Identification of two distinct intron elements involved in alternative splicing of beta-tropomyosin pre-mRNA. Genes Dev, 4: 98-110,  1990. (10.1101/gad.4.1.98)
  34. Mulligan GJ, Guo W, Wormsley S, Helfman DM Polypyrimidine tract binding protein interacts with sequences involved in alternative splicing of beta-tropomyosin pre-mRNA. J Biol Chem, 267: 25480-7,  1992. (10.1016/S0021-9258(19)74066-6)
  35. Gooding C, Roberts GC, Smith CW Role of an inhibitory pyrimidine element and polypyrimidine tract binding protein in repression of a regulated alpha-tropomyosin exon. Rna, 4: 85-100,  1998.
  36. Jin W, McCutcheon IE, Fuller GN, Huang ES, Cote GJ Fibroblast growth factor receptor-1 alpha-exon exclusion and polypyrimidine tract-binding protein in glioblastoma multiforme tumors. Cancer Res, 60: 1221-4,  2000.
  37. Carstens RP, Wagner EJ, Garcia-Blanco MA An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein. Mol Cell Biol, 20: 7388-400,  2000. (10.1128/MCB.20.19.7388-7400.2000)
  38. Le Guiner C, Plet A, Galiana D, et al Polypyrimidine tract-binding protein represses splicing of a fibroblast growth factor receptor-2 gene alternative exon through exon sequences. J Biol Chem, 276: 43677-87,  2001. (10.1074/jbc.M107381200)
  39. Chan RC, Black DL The polypyrimidine tract binding protein binds upstream of neural cell-specific c-src exon N1 to repress the splicing of the intron downstream. Mol Cell Biol, 17: 4667-76,  1997. (10.1128/MCB.17.8.4667)
  40. Liu H, Zhang W, Reed RB, Liu W, Grabowski PJ Mutations in RRM4 uncouple the splicing repression and RNA-binding activities of polypyrimidine tract binding protein. Rna, 8: 137-49,  2002. (10.1017/S1355838202015029)
  41. Norton PA Polypyrimidine tract sequences direct selection of alternative branch sites and influence protein binding. Nucleic Acids Res, 22: 3854-60,  1994. (10.1093/nar/22.19.3854)
  42. Cote J, Dupuis S, Wu JY Polypyrimidine track-binding protein binding downstream of caspase-2 alternative exon 9 represses its inclusion. J Biol Chem, 276: 8535-43,  2001. (10.1074/jbc.M008924200)
  43. Southby J, Gooding C, Smith CW Polypyrimidine tract binding protein functions as a repressor to regulate alternative splicing of alpha-actinin mutally exclusive exons. Mol Cell Biol, 19: 2699-711,  1999. (10.1128/MCB.19.4.2699)
  44. Cartegni L, Chew SL, Krainer AR Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet, 3: 285-98,  2002. (10.1038/nrg775)
  45. Auersperg N, Maines-Bandiera SL, Dyck HG Ovarian carcinogenesis and the biology of ovarian surface epithelium. J Cell Physiol, 173: 261-5,  1997. (10.1002/(SICI)1097-4652(199711)173:2<261::AID-JCP32>3.0.CO;2-G)
Dates
Type When
Created 19 years, 11 months ago (Sept. 21, 2005, 7:57 p.m.)
Deposited 3 years, 2 months ago (June 11, 2022, 1:16 p.m.)
Indexed 4 weeks, 1 day ago (July 28, 2025, 5:10 p.m.)
Issued 21 years, 1 month ago (July 15, 2004)
Published 21 years, 1 month ago (July 15, 2004)
Published Online 21 years, 1 month ago (July 21, 2004)
Published Print 21 years, 1 month ago (July 15, 2004)
Funders 0

None

@article{He_2004, title={Alternative Splicing of the Multidrug Resistance Protein 1/ATP Binding Cassette Transporter Subfamily Gene in Ovarian Cancer Creates Functional Splice Variants and Is Associated with Increased Expression of the Splicing Factors PTB and SRp20}, volume={10}, ISSN={1557-3265}, url={http://dx.doi.org/10.1158/1078-0432.ccr-03-0439}, DOI={10.1158/1078-0432.ccr-03-0439}, number={14}, journal={Clinical Cancer Research}, publisher={American Association for Cancer Research (AACR)}, author={He, Xiaolong and Ee, P. L. Rachel and Coon, John S. and Beck, William T.}, year={2004}, month=jul, pages={4652–4660} }